semaglutide side effects acid reflux reflux: why it happens and how to manage it GLP-1 and GIP-1 receptor agonists

What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy

Untreated symptoms are

Most patients report no noticeable change in appetite suppression, side effects, or energy levels, particularly when switching between equivalent doses

Use AI-powered documentation tools to summarise key findings from the questionnaire into the clinical note, reducing manual transcription and saving 5-10 minutes per consultation